Overall, these findings suggest that ganetespib could serve as an effective therapeutic option, both as a monotherapy and in combination, for treating BRAF(V600E)-mutant melanoma, particularly as a strategy to overcome acquired resistance to selective BRAFi [160]. The gene discussed is BRAF; the disease is melanoma.